Volver a Agenda
Session 5, Track A: Latest Advancements in AI – A Regulatory Perspective
Session Chair(s)
Louise Blythe, MSc
VP & Head, Regulatory Affairs
Bayer Inc. Canada, Canada
Melanie Cote, MS
Senior Manager, Regulatory Affairs
Otsuka, Canada
In the rapidly evolving field of artificial intelligence (AI), regulatory professionals are encouraged to engage with ongoing developments in AI regulatory frameworks and explore how AI can be leveraged within their practices. This session will delve into the emerging AI regulatory framework and its implications for regulatory professionals. Through the use of case studies, participants will gain insights into real-world AI experiences in Regulatory Affairs. The session will also address the benefits, challenges and risks associated with the implementation of AI.
Learning Objective : - Explore Health Canada's emerging artificial intelligence (AI) regulatory framework and its potential impact on regulatory processes
- Discuss real-world case studies to illustrate the application of AI in Regulatory Affairs
- Recognize the benefits, challenges and risks related to the implementation of AI
Speaker(s)
The Use of AI in a Regulatory Framework
Representative Invited
Health Canada, Canada
AI Use Cases
Representative Invited
sanofi-aventis Canada Inc, Canada
Demystifying AI for Regulatory
Representative Invited
AstraZeneca , United Kingdom
¿Tiene una cuenta?